Back to News
Market Impact: 0.25
Oculis Reports New Phase 2 Privosegtor Biomarker Findings In Optic Neuritis
Source: Nasdaq
Healthcare & Biotech
Oculis said new biomarker analyses from its Phase 2 ACUITY trial showed privosegtor reduced increases in blood markers of nerve injury and inflammation versus placebo in patients with optic neuritis. The report describes a positive trial biomarker finding but provides no effect sizes or other numerical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
OCS0.65
More News
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- Palmer Luckey teams with dire wolf billionaire Ben Lamm to launch $200 million Warhound, unleashing genetically engineered clone dogs of war
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Zai Lab raises $250 million in private placement financing
- Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data